Special Issue "Liquid Biopsy in Cancer"
Deadline for manuscript submissions: closed (31 December 2020).
Department of Medicine, University of Udine, 33100 Udine, Italy
Interests: breast cancer; translational research; predictive factors; prognostic factors; liquid biopsy
2. Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, IRCCS CRO Aviano National Cancer Institute, Italy
Interests: translational trials; breast cancer; ctDNA; CTC; circulating biomarkers; endocrine resistance; DNA repair; clinical methodology
Special Issues and Collections in MDPI journals
Precision medicine is becoming the new paradigm in healthcare as it enables treatment optimization, a potential reduction in side effects, and better resources allocation. Liquid biopsy is the cornerstone of this revolution since it provides real-time prognostic and predictive information for advanced cancer patients without the analytical and procedural drawbacks of tissue biopsy.
Several technologies are comprised under the umbrella term of “liquid biopsy”, each with its strengths and peculiarities. In particular, circulating tumor DNA (ctDNA) together with circulating tumor cells (CTCs) and microvesicles are gaining momentum as promising markers for early disease characterization and longitudinal monitoring for resistance detection.
This Special Issue is aimed at summarizing both analytical developments and clinical evidence regarding the application of liquid biopsy across the major cancer types, with a special focus on its clinical utility and how its deployment will ultimately lead to the growing personalization of cancer care.
Prof. Fabio Puglisi
Dr. Lorenzo Gerratana
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- circulating biomarkers
- clinical utility
- precision medicine